La fine pointe de la science du cannabis avec une équipe ancrée au Québec.
Une entreprise d’ici, membre de la famille Emerald Health Therapeutics Inc.
Verdélite est une usine de production de cannabis. Grâce à notre environnement intérieur 100 % contrôlé, nos produits sont de la plus haute qualité et nos récoltes toujours stables.
Située à Saint-Eustache, près de Montréal, Verdélite est une entreprise exploitée par une équipe Québécoise composée de plus de 70 experts. Nous travaillons à développer et mettre en marché des produits de cannabis, faits au Québec et répondant aux besoins des gens d’ici.
Nous utilisons les techniques de pointe de la science pour aider les gens à vivre plus heureux et en meilleure santé. Comme le reste de la famille Emerald Health Therapeutics Inc., nous concentrons nos efforts au développement d’une grande variété de produits de cannabis pour répondre aux besoins de tous.
Chef des Opérations
Vice-président Senior, Affaires Qualité et Réglementation
Verdélite Sciences Inc. est une filiale en propriété exclusive de
Mr. Jiwan is a data driven business leader with over 20 years experience in strategic development , sales and operations management , e-commerce, and developing data and business intelligence solutions. Before joining Emerald, he served in senior leadership positions, including Chief Information Officer and Chief Customer Officer, for established cannabis and healthcare companies, including senior roles at TerrAscend Corp and Shopper’s Drug Mart. With a strong marketing and customer orientation, he has strongly focused on operational excellence and implementing processes to function faster, smarter, and leaner.
Ms. Wong has over 30 years of quality and regulatory management experience in pharmaceutical and life science companies regulated to Canadian, US, European and international requirements. She has been responsible for establishing quality systems and ensuring regulatory compliance through all phases of product development from GPP, GLP, GCP, GMP for cannabis, pharmaceuticals, medical devices, combination products and biologicals. She was previously Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.) and worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta.
Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.
Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.
He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.
Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.